Linagliptin/metformin

Linagliptin/Metformin is a combination drug used for the treatment of Type 2 diabetes. It is a combination of Linagliptin, a dipeptidyl peptidase-4 inhibitor, and Metformin, a biguanide.

Indications

Linagliptin/Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

Mechanism of Action

Linagliptin works by increasing the levels of incretins, which can inhibit the release of glucagon and thereby reduce glucose production. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Side Effects

Common side effects of Linagliptin/Metformin include upper respiratory tract infection, stuffy or runny nose, sore throat, diarrhea, and headache. Serious side effects may include lactic acidosis, pancreatitis, heart failure, and allergic reactions.

Interactions

Linagliptin/Metformin may interact with other drugs including rifampin, topiramate, or other carbonic anhydrase inhibitors.

Contraindications

Linagliptin/Metformin is contraindicated in patients with severe renal impairment, metabolic acidosis, or diabetic ketoacidosis.

See Also

• Type 2 diabetes
• Linagliptin
• Metformin

Linagliptin/metformin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia